Member Info for John2015

CE MARK, Roll out April - 2m tests per week, by End April, Capacity will fill demand across a range of LFT's

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has CE-Marked Mologic Ltd's ('Mologic') lateral flow antigen test for COVID-19, to be sold for professional-use under Omega's VISITECT® brand. The test will provide healthcare professionals with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs.
Having commenced technology transfer late last year Omega has CE-marked the product and is now in the process of completing marketing launch for commercial roll-out which is expected to start in April.
The Company is already in discussion with a number of potential commercial partners looking to order the test post launch.
The Company is well on its way to establishing a lateral flow production capacity of approximately 2 million tests per week by the end of April from its Alva facility in Scotland. This production capacity will be used to produce this VISITECT® branded antigen test for sale to third-party commercial customers.
The Company's production capacity will be used to fulfil demand across a range of lateral flow tests:

THERE MUST BE NEWS DUE WITHIN 2 WEEKS !

peterpaz Me too lost £49k on that one and now I see Anglo putting out PR about their mine and the progress ( TBM now at 87 miles ) when JPM told us all how risky it was and refused to agree bond terms, while they shorted us.
Can't believe how long its taking to find out anything about Orders, TT, Sales ETC.
Meanwhile this is the last Covid stock I hold still blue ( just ) as NCYT and GDR have halved in value in recent weeks while HMG and their respective BOD's seemingly twiddle their thumbs.
Not selling any of them, believe all have good products/opportunities, just waiting ( interminably it feels ) for them to come good.

Makes you wonder where all the tests that have been oredered/produced actually are ?
What have they done with them all and why can't anybody tell us how many actually produced, when and where they are.

This sp is oversold by all the usual measures.
Fundamentals are good, revenue coming in, new products available, market worldwide with at least one test that can detect all variants.
Added 200 more holding, however long it takes until we see fair value - which is much neare £12 than £4 IMO.
GLA LTH

NCYT are sitting on a pile of cash, have a dispute with DHSC but still have very good revenue and the only test that can detect all variants. Why are they tanking ?

How about some analysis of the financials and market opportunities rather than gloating as the sp falls ?
It seems to me that ODX GDR and NCYT are al caught up in some kind of "Its all over now" from the public and " can we get away with the cheapest crap tests" from HMG - both completely wrong. ODX have good products but need authorisations and info on Technical Transfers etc, GDR also waiting on authorisations but have a tremendous deal with Beckman, NCYT are sitting on a pile of cash, have a dispute with DHSC but still have very good revenue and the only test that can detect all variants. Why are they all tanking ?

dick

So I've topped up again today and dropped my average by another 35p.
Now we need some good news - plenty of opportunity, lots of potential all over the world with a good range of products. If HMG can't see that it’s their loss IMO.
GLA LTH as always no advice inrtended, do your own research and make up your own mind.

agreed Porky

Porky your 19:08 Agreed. Topped up Fri pm and averaged down. Still all to play for imo.
Each to their own of course.

Lets hope GM HAS A PLAN b - waiting to see what that is - a comment from the company about future strategy, not relating in any way to DHSC or UK (so no problem with legalities) would be very welcome.

I think the writing was on the wall when Grant Shapps said in the news this morning that pcr tests would be required for interantional travel but at £120 they were too expensive. Maybe that was a final shot from HMG trying to drive the cost down ?
Presumably NCYT said they could not/would not drop the price ( I'm assuming its their test - anyone know ) and the rest as they say is (expensive ) history.
Perhaps that story isn't over yet though what do you all think ?
Also NCYT still retain 50% of their revenue even without the DHSC contract.

Simon seeing as I hold NCYT as well I sincerely hope you are right.
Sadly lost far more on what I thought was a safer share than I made on this "riskier" one.
Starting to think the government are seeing just how many covid stocks they can bankrupt.

So according to HL I'm up but in reality - as the bid went down 0.05 while the sp went up I'm actually down ?
Funny old game - 23% spread looks really reasonable though.

Bad news but way oversold in my view the fundamentals are good, lots of cash still a huge market even without DHSC so added another 15% to my holding and dropped my average by 40p.
GLA LTH

Chas there's always a silver lining.

See NCYT the ill informed rushing for the doors.

Still holding by the way as I think eventually HMG will realise their mistake and if they don't the rest of the world will.

After confusing everybody to a point where no one knows who is selling what to who and trashing the sp of most Covid stocks the government have decided to dump NCYT as well.
ApStill it’s not like they've wasted billions on crap LFT,s is it.

To add 20,000 shares here and average down.
GLA LTH